Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05970549

Deployment of Irrigating Intraventricular Catheter System for Intraventricular Hemorrhage

The purpose of this research study is to evaluate the safety and outcomes associated with the use of IRRAflow® System catheters in externally draining intracranial fluid to reduce intracranial pressure. This study will be comparing the IRRAflow® system to standard of care catheters used in the same procedure. The IRRAflow® system is FDA approved for this procedure.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Intracranial hemorrhagic conditions can rapidly cause brain damage and often considered life- threatening. Of these, Intracerebral hemorrhagic (ICH) is the most common type of hemorrhagic stroke and is associated with higher rates of morbidity and mortality than all stroke subtypes.

Management of hemorrhagic patients is typically orchestrated by neurosurgeons and neuro-intensivists. Comprehensive care should include surveillance and monitoring of Intra Cranial Pressure (ICP), Cerebral Perfusion Pressure (CPP), and hemodynamic function. Furthermore, prevention of infection, complications of immobility through positioning and mobilization within physiological tolerance play an important role in optimizing outcomes after ICH.

There are multiple approaches to facilitating Cerebrospinal Fluid (CSF) drainage and monitor ICP. Routinely, intracranial pressure is measured by use of devices inserted into the brain parenchyma or cerebral ventricles. A Ventricular Catheter (VC) inserted into the lateral ventricle allows for drainage of CSF to help reduce ICP. Although CSF drainage is a vital sequence in patient management, there are reported risks including infection and limitations related to erroneous readings associated with current ICP monitors. Physicians lack the appropriate tools to employ active intermittent aspiration and drainage with continuous ICP monitoring.

The current clinical study is being initiated to evaluate the hypothesis that active irrigation by IRRAflow will reduce the time needed for clearance of intraventricular blood from intraventricular space.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >=18 years of age
  • Intraventricular hemorrhage documented on head CT or MRI scan
  • Need of cerebrospinal fluid drainage
  • Indication for active treatment evaluated by the treating physicians
  • Signed informed consent obtained by patient or Legal Authorized Representative
  • Treatment possible within 72 hours of ictus

Exclusion criteria

  • Patient has fixed and dilated pupils
  • Pregnant or nursing women (fertile female participants will be required to take a validated pregnancy test for evaluation of pregnancy)

Treatment and study plan

IRRAflow® Active Fluid Exchange System

Device

All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm.

Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise.

Other names: IRRAflow® CNS System

Traditional extraventricular drain

Device

The retrospective analysis will be performed on the last 60 traditional external ventricular drains.

Non-contrast head CTs

Procedure

Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.

Primary outcomes

  1. Residual blood volume

    Time frame: At day 5

    Residual blood volume on post bleed day 5

Secondary outcomes

  1. Serious adverse events

    Time frame: up to 48 hours post-procedure

    Number of serious adverse events

  2. Hospital quality metrics

    Time frame: up to 48 hours post-procedure

    Length of stay in the NSICU as a quality metrics

  3. Length of stay in the NSICU

    Time frame: up to 48 hours post-procedure

    Length of hospital stay in the as a quality metrics

  4. Direct hospitalization costs

    Time frame: up to 48 hours post-procedure

    Direct hospitalization costs

Study contacts

Contact information is provided by the study sponsor or research team.

Emily Svendsen

CONTACT

[email protected]

(212) 241-3238

Sydney Edwards

CONTACT

[email protected]

(212) 241-2524

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Collaborators

  • ClearPoint Neuro

Registry information

Official study title

DIVE: Deployment of Irrigating Intraventricular Catheter System for Intraventricular Hemorrhage

Acronym: DIVE

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Aug 1, 2023
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.